<DOC>
	<DOCNO>NCT02477150</DOCNO>
	<brief_summary>To study safety immunogenicity herpes zoster vaccine patient SLE .</brief_summary>
	<brief_title>Safety Immunogenicity Zoster Vaccine SLE</brief_title>
	<detailed_description>Herpes zoster ( HZ ) ( Shingles ) painful condition cause reactivation varicella zoster virus ( VZV ) remain dormant primary infection . HZ reactivation may cause significant morbidity post-herpetic neuralgia even mortality disseminate infection , particularly immunocompromised individual . HZ vaccine ( Zostavax ) essentially larger-than-normal dose chickenpox vaccine , contain Oka strain live attenuate VZV . Zostavax show safe protective immunocompetent elderly population ( &gt; 60 year age ) reduce reactivation HZ 51 % post-herpetic neuralgia 66 % . Another study also demonstrate efficacy Zostavax reduce HZ infection 70 % adult age 50-59 year . Data regarding use HZ vaccine patient rheumatic disease scant . A recent observational study involve 463,541 US patient rheumatoid arthritis , inflammatory bowel disease , psoriatic arthritis ankylose spondylitis show 4 % patient receive HZ vaccination . After median observation period 2 year , rate HZ reactivation among vaccinated patient significantly low unvaccinated group ( hazard ratio 0.61 [ 0.52-0.71 ] ) . Among 633 patient expose biologics time vaccination , case HZ varicella infection occur subsequent 42 day vaccination . Thus , vaccine appear safe patient autoimmune rheumatic disease even receive biological agent . HZ reactivation fairly common patient systemic lupus erythematosus ( SLE ) . However , data regard HZ vaccination SLE patient generally lack . Safety efficacy HZ vaccination recently demonstrate immunocompromised group HIV infection , post-chemotherapy hematological malignancy . According 2011 EULAR recommendation , HZ vaccination may consider patient autoimmune inflammatory rheumatic disease provide less seriously immunosuppressed . The current study design test immunogenicity safety HZ vaccine ( Zostavax ) patient stable SLE receive minimal immunosuppressive therapy maintenance .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . SLE patient fulfill ≥4 1997 ACR ( 17 ) 2012 SLICC/ACR criterion SLE ( 18 ) 2 . Age ≥18 year 3 . Clinically inactive disease SELENASLEDAI score &lt; 6 ( see ) receive stable dose immunosuppressive agent ≥6 month 4 . History varicella ( chickenpox ) herpes zoster infection past 5 . Willing comply study procedures 1 . Active infection , include upper respiratory tract infection 2 . Active untreated tuberculosis 3 . Human immunodeficiency virus ( HIV ) infection 4 . Lymphocyte count &lt; 500/mm2 5 . Reduced serum IgG , IgA IgM level ( normal range ) 6 . Serum creatinine &gt; 200umol/L 7 . History hematological malignancy ( eg . lymphoma , leukaemia ) solid tumor 8 . Patients receive dos immunosuppressive agent exceed follow : Prednisolone ( &gt; 15mg ) equivalent Azathioprine ( &gt; 100mg/day ) Mycophenolate mofetil ( &gt; 500mg/day ) Cyclosporin A ( &gt; 100mg/day ) Tacrolimus ( &gt; 3mg/day ) Methotrextate ( &gt; 15mg/week ) Cyclophosphamide ( dose ) Biological agent eg . rituximab , belimumab ( dose ) 9 . Patients pregnant plan become pregnancy within one year study entry 10 . Patients give write consent ( mentally incapable illiterate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>lupus</keyword>
</DOC>